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Abstract: Colony-forming unit (CFU) assay is a short-term culture assay used for the detection of functionally active 
hematopoietic progenitor cells (HPCs) in the in vitro setting. This potency assay enables the identification of colony-
producing HPCs in any type of hematopoietic stem cell/progenitor product (HSC/P) including bone marrow (BM), cord 
blood (CB) and mobilized peripheral blood (MPB). It has been shown that the frequency of HPCs in BM, MPB and CB 
cellular products directly correlates with the engraftment of both neutrophils and platelets as well as with the overall 
survival of recipients following hematopoietic stem cell transplantation which makes the CFU assay a good quality 
parameter for the prediction of engraftment success. The aim of this article is to provide an overview of different 
approaches to setting up the CFU assay with an emphasis on different sample preparation techniques, cell plating density 
and colony identification and enumeration used by different laboratories. 
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During adulthood, the majority of multipotent 
hematopoietic stem cells (HSCs) reside in bone marrow 
(BM). There they sustain the balance between the 
processes of self-renewal and differentiation, thus at the 
same time providing the pool of cells with self-renewal 
ability and the progeny of cells that proceed further into 
differentiation. Differentiation of HSCs to mature blood 
cells is a multiphase process that includes several 
intermediate stages. Multipotential progenitors give rise 
to committed progenitors of the two main branches of 
the hematopoietic lineage; common myeloid progenitors 
(CMPs) and common lymphoid progenitors (CLPs) 
(Figure 1). Downstream differentiation of CMPs and 
CLPs results in lineage-restricted progenitors that 
subsequently differentiate to completely functional 
mature blood cells.1  
Although the best demonstration of the existence and 
function of HSCs in vivo is the hematopoietic recovery 
of a myeloablated recipient after HSC transplantation 
(HSCT), several in vitro assays have been developed in 
order to provide a comprehensive insight into the 
biological properties, activity and quantity of HSCs.  
The most primitive HSCs can be identified in long-term 
culture (LTC) assays that are performed by culturing 
hematopoietic cells on an adherent monolayer of stromal 
cells during several weeks. In this model, stromal cells 
derived from human BM promote survival, self-
renewal, proliferation and differentiation of so-called 
long-term culture-initiating cells (LTC-ICs). Following 
5-8 weeks of cell culture, newly produced non-adherent 
cells can be collected and cultured in a short-term 
culture assay in order to determine the clonogenic 
potential of initial LTC-ICs.2 Another variant of the 
LTC assay is the cobblestone area-forming cell (CAFC) 
assay in which phase dark areas of proliferating cells 
(„cobblestone areas“) are visually detected beneath the 
stromal layer after several weeks of culture. The CAFC 
numbers  have been  shown to  directly correlate  to  the  
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Figure 1. Schematic representation of hematopoietic development. 
Legend: HSC - hematopoietic stem cell; MPP - multipotential progenitor; CMP - common myeloid progenitor; CLP - common lymphoid progenitor; 
GMP - granulocyte/macrophage progenitor; MEP - megakaryocyte/erythroid progenitor; EP - erythroid progenitor; MkP - megakaryocyte progenitor. 
Depending on the formulation of the culture medium, colony-forming unit (CFU) assay can identify multipotential progenitor (CFU-GEMM, CFU-
granulocyte, erythroid, monocyte/macrophage, megakaryocyte) and lineage-directed progenitors (BFU-E - burst-forming unit erythroid; CFU-E, CFU-
erythroid; CFU-M, CFU-monocyte/macrophage; CFU-G, CFU-granulocyte; CFU-Mk, CFU-megakaryocyte). 
 
 
BM repopulating ability in the murine model. However, 
in the case of human samples the results of CAFC assays 
showed variable results depending on the type of sample 
and the feeder layer used.3  
Although LTC assays can provide important 
information about HSC biological properties, their use 
is mainly limited to scientific research. On the other 
hand, the short-term culture assay, popularly called the 
colony-forming unit (CFU) assay, is frequently used as 
a potency test in the case of HSCT. The CFU assay was 
developed with the aim of detecting hematopoietic 
progenitor cells (HPCs) that originate from HSCs.4 It 
enables the identification of multipotential CFU-
granulocyte, erythroid, monocyte/macrophage, 
megakaryocyte (CFU-GEMM) progenitors that have 
multi-lineage differentiation potential and limited self-
renewal ability (Figure 1). Furthermore, the CFU assay 
enables the detection of more mature lineage-restricted 
progenitors including CFU-granulocyte/macrophage 
(CFU-GM, CFU-M and CFU-G), burst-forming unit 
erythroid (BFU-E) and CFU-erythroid (CFU-E) that 
lack self-renewal ability and can differentiate into cells 
of one or two hematopoietic lineages (Figure 1).5 
Since its introduction into transplantation medicine, the 
CFU assay has become the benchmark in vitro assay that 
can be used for the detection of biologically active HPCs 
in any type of hematopoietic stem cell/progenitor 
product (HSC/P) including BM, cord blood (CB) and 
mobilized peripheral blood (MPB). The quality of a 
HSC/P product is usually assessed at several different 
processing and storage points in order to monitor the 
effect of manipulations such as volume reduction, red 
blood cell (RBC) removal, cryopreservation and 
thawing on viability and functional capacity of the 
cells.5-8 In this regard, one of the most important quality 
assessment parameters is CD34-positive cell count.6 The 
CD34 marker, the so-called “stem cell marker”, is 
expressed by a very small proportion of HSCs. The 
majority of CD34-positive cells in HSC/P products are 
HPCs, and not all of them participate in the engraftment 
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process following transplantation. In this regard, CFU 
assay can provide information about the quantity of 
functionally active CD34-positive HPCs that are 
capable of producing hematopoietic colonies. In this 
way, CFU assay can be used to predict engraftment 
success together with other product quality parameters. 
For this reason, many transplant centres include the CFU 
assay in the quality control of HSC/P products despite 
the fact that its results are a release criterion only in the 
case of CB products.6 
The aim of this article is to provide an overview of the 
CFU assay as a tool for defining HPC content in human 
cell products with an emphasis on different culture 




SETTING UP THE CFU ASSAY 
The CFU assay is usually performed by culturing a 
sample of HSC/P product in a semi-solid matrix 
supplemented with a combination of recombinant 
human cytokines. Different types of complete media 
formulated for optimal growth and differentiation of 
hematopoietic cells are now commercially available. 
The matrix of choice in most media is methylcellulose 
since it provides optimal viscosity necessary to support 
the formation of colonies derived from individual 
progenitor cells. Furthermore, methylcellulose is 
chemically inert and stabile in the environment with a 
variable pH.8 Nevertheless, agar- and collagen-based 
media are also available and can be used for the 
detection of pure megakaryocyte progenitors since their 
colonies normally do not grow in methylcellulose.9 
Proliferation and differentiation of progenitor cells 
during culture are stimulated by the presence of 
recombinant cytokines in the culture medium. Such a 
cocktail of cytokines usually includes, but is not limited 
to, stem cell factor (SCF), granulocyte macrophage 
colony-stimulating factor (GM-CSF), granulocyte 
colony-stimulating factor (G-CSF), interleukin 3 (IL-3) 
and erythropoietin (EPO). The choice of cytokine 
formulation of the medium depends on the purpose of 




Samples collected from BM and CB products with high 
hematocrit levels usually have to be processed prior to 
setting up the CFU assay. Large number of RBCs in 
short-term cell culture can interfere with colony growth 
and reduce the accuracy of the CFU assay. Therefore, in 
such cases RBC depletion needs to be performed.  
In the case of BM samples, RBCs can be lysed with 
ammonium chloride or, alternatively, isolation of BM 
mononuclear cells by density gradient separation can be 
performed. The latter method provides cell suspension 
enriched with hematopoietic progenitors deprived of 
interfering RBCs, while cell suspension obtained by 
RBC lysis provides all leukocyte populations. 
Difference in the content of cell populations resulting 
from different methods of cell suspension preparation 
should be considered when adjusting cell seeding 
density. 
The gravity sedimentation using RBC aggregating 
agents is a standard method of CB processing by use of 
an automated system. However, depending on the 
processing method used, hematocrit of post-processed 
CB units might remain high. In such cases, further 
depletion of RBCs in CB samples is required before 
setting up the CFU assay. There are two common 
methods of eliminating RBCs from CB samples. One 
strategy includes the use of a gravity sedimentation 
medium that enables the isolation of nucleated cells 
from CB samples by promoting the formation of RBC 
aggregates that sediment much faster than nucleated 
cells.  The other strategy includes magnetic depletion of 
RBCs using immunomagnetic particles that bind to 
Glycophorin AB+ cells. This method is less laborious 
and time consuming and it has shown good results in 
both fresh and frozen CB samples.  
In the case of MPB samples, the RBC depletion step is 
not needed as the hematocrit level in this type of 
products is very low.   
The choice of the RBC depletion method used for 
preparing the cell suspension for setting up the CFU 
assay greatly depends on the expectations from the assay 
results. If the expected information is just the qualitative 
result (growth/no growth of CFU colonies), any of the 
described methods of sample preparation will be 
appropriate. However, if the expected information is the 
quantitative result that could be correlated with absolute 
CD34-positive cell number, then a more volumetric 




Plating cell density 
Plating cell density should be adjusted according to the 
cell source (Table 1). It is considered that cultures with 
20-80 colonies per dish ensure statistically accurate 
enumeration. Underplating of cells can result in a small 
number of colonies which can lead to large variations 
between replicates. On the other hand, overplating of 
cells can result in overgrowth of colonies which can 
cause difficulties in identifying individual colonies 
and/or inhibit colony growth due to excessive 
consumption of nutrients in the medium. Therefore, in 
order to set up the optimal CFU assay strategy in any 
laboratory, validation studies focusing on the methods 
of cell suspension preparation and cell plating density 
should be performed. 
If the aim of the CFU assay is only to demonstrate the 
presence of biologically active HPCs in a certain HSC/P 
product, then the initial plating cell density should be 
adjusted to those expectations. Following the initial 
RBC depletion step where needed, plating cell density 
should be adjusted according to the cell source as shown  
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Table 1. Recommended plating concentrations for different cell 
samples 
HSC/P product 
TNC/ml of complete 
media 
BM - RBC depleted 5x104 (2x104 – 1x105) 
BM - mononuclear cells  2x104 (1x104 – 5x104) 
CB - RBC depleted 2x104 (1x104 – 4x104) 
MPB - mononuclear cells 2x104 (1x104 – 5x104) 
CD34+ selected cells (BM, CB, MPB) 500 (500 – 2x103) 
Modified according to Helgason et al. (5) and Technical Manual: 
Human Colony-Forming Cell (CFC) Assays Using MethoCult, 
Version 4.0.0 (STEMCELL Technologies) 
Legend: HSC/P - hematopoietic stem cell/progenitor; TNC - total 
nucleated cells; BM - bone marrow; RBC - red blood cells; CB - cord 
blood; MPB - mobilized peripheral blood 
 
 
in Table 1. In this case, the adjustment of cell 
concentration can include several dilutions in order to 
achieve the final concentration of cells in the culturing 
semi-solid medium. 
On the other hand, if the aim of the CFU assay is to 
provide the number of CFU colonies per volume of 
HSC/P product and correlate it with the absolute number 
of CD34-positive cells per volume, then multi-dilution 
approach is not appropriate because with every further 
dilution the number of cells deviates more from initial 
cell concentration in the product. Although one dilution 
step is almost always necessary, multiple dilutions 
should be avoided. In the case of BM and CB samples 
with high hematocrit levels, the RBC depletion step is 
inevitable. In this situation the immunomagnetic RBC 
depletion approach should be considered since it 
includes only one dilution step and provides better 
approximation of CFU-producing HPCs in the product.  
In the case of MPB samples, the concentration of cells 
in the product is usually very high, and the volume of 
cells that should be transferred directly to cultivating 
media using semi-automatic pipette is too low to 
measure. Therefore, in these samples, one dilution step 
is also needed in order to obtain the cell concentration in 




Enumeration of colonies 
The majority of hematopoietic colonies growing in 
culture achieve their maximum number and size after 
approximately 14 days, when they can be identified 
based on their morphology. If the information about the 
total colony number needs to be obtained within a 
shorter time frame, the CFU assay can be performed 
using a specially formulated medium that enables the 
enumeration of colonies after 7 days of culture. In this 
type of CFU assay, the identification of different colony 
types is not possible since colonies are much smaller and 
contain less differentiated cells.8 Therefore, this type of 
assay can only provide the total number of colonies but 
cannot give information about progenitor lineages.   
In standard 14-day CFU assays, normal CFU-GM 
colonies consist of at least 40 granulocyte and 
macrophage cells that commonly spread out from a 
distinct dense colony centre (Figure 2A). In some cases, 
one CFU-GM colony can consist of multiple clusters 
that are grouped together (Figure 2B). BFU-E and CFU-
E colonies are easily recognizable due to their red or 
brownish color that is derived from hemoglobin.8 BFU-
E colonies arise from more immature progenitors and 
although they can appear as only one compact cluster, 
they usually form several clusters or bursts (Figure 2C). 
On the other hand, CFU-E colonies are derived from 
more mature erythroid progenitors and are typically 
found in BM samples. They contain up to 200 
erythroblasts in one or two clusters.8 Colonies derived 
from multipotential CFU-GEMM progenitors are 
usually more abundant in CB samples. A typical CFU-
GEMM colony is often large and contains both cells of 
erythroid and non-erythroid lineages including 





















Figure 2. Hematopoietic colony identification under inverted 
microscope (10x objective). (A) Colony derived from CFU-GM 
with one dense centre. (B) Multi-cluster colony derived from CFU-
GM. (C) Multi-cluster colony derived from BFU-E. (D) Colony 
derived from multipotential CFU-GEMM progenitor. 
 
 
Enumeration of colonies is usually performed by trained 
individuals using an inverted microscope. Nevertheless, 
manual scoring of colonies is inherently subjective, 
which implies that inter-individual variations associated 
with colony counting can never be completely 
eliminated.10 Recently, automated imaging instrument 
equipped with sophisticated image acquisition and 
analysis software that identifies, classifies and counts 
hematopoietic colonies has been developed (Figure 3). 
This automated system has been designed with the aim 
to   standardize  the  enumeration  of  colonies,  enhance 
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Figure 3. Image and analysis of a CFU assay using automated CFU assay reader STEMvisionTM (StemCell Technologies). (A) Display of colony 
analysis results in STEMvisionTM Colony Marker Application. (B) Enlarged view of different types of hematopoietic colonies. 
 
 
reproducibility of the CFU assay and improve inter-
laboratory comparability of the results. 
 
CONCLUSION 
Although the amount of CD34-positive cells in 
transplanted HSC/P products usually correlates with the 
engraftment in the patients, in some cases the potency of 
the transplant is lower than expected, which might 
consequently result in graft failure.11 Therefore, if the 
quality assessment of the HSC/P product is based 
primarily on the flow cytometric analysis of CD34-
positive cells, the information about the real potency of 
the graft is lacking.12 This is the rationale for use of 
functional assays like the CFU assay which can give a 
much better correlation with potency. It has been shown 
that the frequency of HPCs in BM, MPB and CB cellular 
products directly correlates with engraftment of both 
neutrophils and platelets as well as with the overall 
survival of recipients following HSCT.13-17 
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However, performing this assay can be very challenging 
from the technical point of view for several reasons. For 
each tissue source, thorough validation procedures need 
to be performed to ensure that the assay results will not 
over- or underestimate the potency of the tested product. 
The number of the produced colonies depends on the 
plating cell density and on the CD34-positive cell 
content in the HSC/P product. The ideal situation would 
be to adjust the plating density according to the CD34-
positive cell count. However, due to technical or 
organizational difficulties this information is not always 
available at the time of the CFU assay set-up, and in such 
cases the plating density has to be adjusted according to 
the total nucleated cell (TNC) count instead.   
Another issue is that cell plating, enumeration and 
identification of colonies is usually performed manually, 
which also contributes to subjectivity and, consequently, 
to a high level of variation in inter-laboratory results. In 
this regard, the proficiency testing program for the CFU 
assay has been developed. This program is aimed at 
critical points in setting up the CFU assay and enables 
inter-laboratory comparison of the obtained results. In 
addition to that, an automated imaging system has been 
designed with the aim of increasing the objectivity of the 
enumeration and identification of colonies. Although 
this is a step forward in the standardization of CFU assay 
results, there is only one type of automated CFU assay 
reader commercially available at the moment 
(STEMvisionTM, StemCell Technologies).  
In conclusion, the CFU assay is a laborious and time 
consuming assay but it provides valuable and relevant 
information about biological properties of the HSC/P 
product which could be correlated with engraftment 
success. The CFU assay can indicate the real potency of 
the graft and should be included in the quality 
assessment of all HSC/P products. Therefore, in order to 
ensure that the engraftment process does not fail because 
of low HSC/P potency, the decision about the release of 
the HSC/P product for clinical transplantation should be 
based not only on the CD34-positive cell content but on 
the graft potency as well.  
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